Under the

Approved for use through 03/31/2007. OMB 0651-0021 U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANGRAGESE LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

ATTORNEY'S DOCKET NUMBER 529282002100

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

**CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** 10/581,412 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/AU2004/001690 3 December 2004 3 December 2003 TITLE OF INVENTION AZOLE-BASED KINASE INHIBITORS APPLICANT(S) FOR DO/EO/US Christopher John BURNS et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. х This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must 3 include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. d. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 9 An English language translation of the annexes of the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 12. 13. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. 14 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 18 A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 19.

PTO-1390 (Rev. 07-2005)

Approved for use through 03/31/2007. OMB 0651-0021

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/581,412			INTERNATIONAL APPLICATION NO. PCT/AU2004/001690		ATTORNEY'S DOCKET NUMBER 529282002100		
20. x Other items	s or informa		B/08a/b (1 page plus Receipt Postcard	duplicat	e); 8 references	s;	
		e been submitte	ed :))		\$200	S CALCULATION	S PTO USEONLY
21. Basic nat					ради	<u> </u>	
If the written opinion p prepared by IPEA/I	repared by IS JS indicates a	all claims satisfy p	national preliminary exam rovisions of PCT Article 3	33(1)-(4)	\$0	\$	
If the written opinion o IPEA/US indica Search fee (37 CFR 1 International Se International Search R previously com	tes all claims .445(a)(2)) ha earching Auth teport prepare municated to	or the internationa satisfy provisions as been paid on the orityed by an ISA other the US by the IB.	I preliminary examination of PCT Article 33(1)-(4) e international application than the US and provide	n to the US	\$0 SPTO as an \$100 ffice or \$400	\$	
	AL OF 21, 22					\$ 0.0	00
sequence lis electronic m	iting in compli edium) (37 Cl	ance with 37 CFR FR 1.492(j)).	ed in paper over 100 she t 1.821(c) or (e) or computs of paper or fraction the	iter progra			
Total Sheets Extr	a Sheets		additional 50 or fraction up to a whole number)		RATE		
- 100 =	/50 =				x \$250.00	\$	
Surcharge of \$130 for after the date of comm			e, examination fee, or the (37 CFR 1.492(h)).	oath or de	eclaration	\$	
CLAIMS	NUN	MBER FILED	NUMBER EXTRA		RATE		
Total claims		- 20 = - 3 =	<u> </u>	X			
Independent claims MULTIPLE DEPENDI				X +			
		,, ( app,	TOTAL OF A	ABOVE CA	LCULATIONS =	\$ 0.0	00
X Applicant clair	ns small entit	y status. See 37 (	CFR 1.27. Fees above a	re reduced	l by ½.	0.00	
					SUBTOTAL =	\$ 0.0	00
Processing fee of \$13 claimed priority date (			ranslation later than 30 m	nonths fron	n the earliest	\$	
				TOTAL N	ATIONAL FEE =	\$	0.00
Fee for recording the by an appropriate cov	enclosed assi er sheet (37 (	gnment (37 CFR CFR 3.28, 3.31). \$	1.21(h)). The assignmen 40.00 per property	t must be a	accompanied +	\$	
						\$	
			то	TAL FEES	S ENCLOSED =	\$	0.00
						Amount to be refunded:	\$
			<u>.</u>			Amount to be charged	\$ 0.00

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$	to cover the above fees is enclosed.	
b. Please charge my Deposit Account No A duplicate copy of this sheet is enclosed.	in the amount of \$	to cover the above fees.
	charge any additional fees which may be required	, or credit any overpayment to Deposit
d. Fees are to be charged to a credit card. V should not be included on this form.	VARNING: Information on this form may become rovide credit card information and authorization of	e public. Credit card Information on PTO-2038
NOTE: Where an appropriate time limit under 37 filed an granted to restore the International App	7 CFR 1.495 has not been met, a petition to re dication to pending status.	vive (37 CFR 1.137(a) or (b)) must be
SEND ALL CORRESPONDENCE TO:	Kate H.	Mushige
	SIGNATURE	U
Kate H. Murashige MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, Califomia 92130-2040	Kat	e H. Murashige
CUSTOMER NUMBER: 25225	REGISTRATIO	29,959
	REGISTRATIO	NNOMBER
		ATTODUENO DOCKET NUMBER
U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/581,412	INTERNATIONAL APPLICATION NO. PCT/AU2004/001690	ATTORNEY'S DOCKET NUMBER 529282002100
	posited with the LLC Destal Convice with sufficien	nt poetage as First Class Mail, in an
I hereby certify that this correspondence is being de envelope addressed to: MS PCT, Commissioner for	r Patents, P.O. Box 1450, Alexandria, VA 22313	I-1450, on the date shown below.
Dated September 22 2006 Signatur	e: Ywly (iv	Judy Calem)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 22-2006

Signature (Judy Collem)

Patent Docket No. 529282002100

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Christopher John BURNS et al.

Serial No.: 10/581,412

Filing Date: (Int'l) December 3, 2004

For: AZOLE-BASED KINASE INHIBITORS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 1 and 2 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on January 20, 2005, directed to a counterpart international or foreign application and have not been previously cited.

	This Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
$\boxtimes$	Within three months of the application filing date or before mailing of a first Office Action
	on the merits; accordingly, no fee or separate requirements are required. However, if
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notice of Allowance.
ė	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
	this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 529282002100.

Dated: September 2, 2006

Respectfully submitted,

Kate M. Murashige

Registration No.: 29,959 MORRISON & FOERSTER LLP

By Kate & Muash

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-5112

	<del>-</del>						
Substitute for form 1449/PTO				Complete if Known			
Suc	ostitute for form 1449/P10			Application Number	10/581,412		
10	NFORMATIO	N DI	SCLOSURE	Filing Date	(Int'l) December 3, 20	004	
STATEMENT BY APPLICANT				First Named Inventor	Christopher John BU	RNS	
J	IAILIVILIAI	<b>D</b> , ,	ALL LIOAN	Art Unit	Not Yet Assigned	1624	
	(Use as many si	neets as	s.necessary)	Examiner Name	Not-Yet-Assigned	z.c.	Tucker
Sheet	1	of	1	Attorney Docket Number	529282002100		

	U.S. PATENT DOCUMENTS					
Cyaminas	0:1-	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
	Cite No. <sup>1</sup>		Name of Calondo	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
/Z. 1./	1.	WO-00/062778	10/2000	Bristol Myers Squibb				
2.1./	2.	WO-03/099811	12/2003	Cytopia Ltd				

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. There office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. The following the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> <sup>2</sup>
<del>/Z.T</del>	3.	International Search Report for PCT/AU2004/001690, mailed on January 20, 2005, 2 pages	
ğ	4.	KOZMA et al., EMBO J. (1988) 7:147-154	
	5.	SADOWSKI et al., Mol. Cell. Biol. (1986) 6:4396-4408	
8 8	6.	SPIOTTO and CHUNG, Prostate (2000) 42:88-98	
W	7.	WILKS and KURBAN, Oncogene (1988) 3:289-294	
/Z.T./	<del>/</del> 8.	WILKS et al., Mol. Cell. Biol. (1991) 11:2057-2065	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Zachary Tucker/	Date 05/09/2008	. [
Signature	/Edditory Fdorson	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.